ABSTRACT
The anticardiolipin (aCL) test has been widely used by physicians since the mid-1980s for diagnosing patients with antiphospholipid syndrome (APS). Establishment of this diagnosis has enabled effective management of patients with recurrent thrombosis and recurrent pregnancy losses. The test was first established in 1983 as a radioimmunoassay and soon thereafter converted into an enzyme-linked immunosorbent assay (ELISA). The other test commonly used in the diagnosis of APS is the lupus anticoagulant (LA) test. The aCL ELISA is sensitive for the diagnosis of APS but lacks specificity. On the other hand, the LA assay, although more specific, is not as sensitive as the aCL ELISA. More specific tests are now available such as the anti-β2 glycoprotein I (anti-β2GPI) assay, the antiprothrombin assay, and other ELISAs that use negatively charged phospholipids instead of cardiolipin to coat the plates.
In the past 25 years, there have been numerous efforts to standardize aCL, LA, and anti-β2GPI tests but there are still reports of significant intra- and interlaboratory variation in results for all three assays.
This article discusses in detail the clinical value of these tests, technical problems associated with their use, the current laboratory classification criteria for diagnosis of APS, and possible new and better assays that will be available in the near future for diagnosis of APS.
KEYWORDS
Anticardiolipin antibodies - antiphospholipid syndrome - antiphospholipid antibodies - ELISA
REFERENCES
Antiphospholipid syndrome . In: Klippel JH, Dieppe PA Rheumatology. London, United Kingdom; Mosby-Year Book 1994: 32.1-32.6
2 glycoprotein I enhances cardiolipoin-binding activity but is not the antigen for antiphospholipid antibodies.
Br J Haematol.
1992;
82
565-570
2 glycoprotein I (apolipoprotein H).
Proc Natl Acad Sci U S A.
1990;
87
4120-4124
2 glycoprotein I in the absence of phospholipid.
J Immunol.
1995;
154
954-960
2 glycoprotein I (apolipoprotein H).
Proc Natl Acad Sci U S A.
1990;
87
4120-4124
2 glycoprotein I with human blood platelets: influence upon the ADP-induced aggregation.
Thromb Haemost.
1985;
54
397-401
th International Symposium on Antiphospholipid Antibodies.
J Rheumatol.
1998;
25
156-162
2 glycoprotein I.
Br J Haematol.
1992;
81
568-573
2 glycoprotein I antibodies.
Arthritis Rheum.
1999;
42
2461-2470
2 glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus.
Am J Med Sci.
1999;
318
53-60
2 -glycoprotein-I antibodies in preeclampsia.
Obstet Gynecol.
2003;
102
294-300
2 glycopotein I.
Thromb Haemost.
1999;
81
929-934
2 glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding.
J Immunol.
1995;
154
954-960
2 glycoprotein I antibodies: a marker of antiphospholipid syndrome?.
Lupus.
1995;
4
122-130
2 glycoprotein I.
Br J Haematol.
1992;
81
568-573
2 glycoprotein with lupus circulating anticoagulant and thrombosis in SLE.
Am J Med.
1992;
93
181-186
2 glycoprotein 1 than with antiphospholipid antibodies.
J Rheumatol.
1995;
22
1899-1906
2 glycoprotein 1 in patients with antiphospholipid syndrome.
J Clin Lab Anal.
1998;
12
293-297
2 glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women.
Hum Reprod.
1996;
11
509-512
2 glycoprotein antibodies: detection and association with thrombosis.
Br J Haematol.
1995;
89
397-402
2 glycoprotein antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance.
Lupus.
1996;
5
587-592
2 glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus.
Arthritis Rheum.
1996;
39
1466-1474
2 glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.
J Exp Med.
1994;
179
457-462
2 glycopotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome.
Blood.
2003;
102
2717-2723
2 glycoprotein (β2 GPI) test?.
, [abstract]
Arthritis Rheum.
2004;
S67
2 glycopotein I contribute to the better characterization of the antiphospholipid syndrome?.
Lupus.
1999;
8
430-438
2 glycopotein I antibody provide additional information in patients with thrombosis.
Thromb Res.
2003;
111
29-32
2 glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group.
Thromb Haemost.
2002;
88
66-73
2 glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies.
J Thromb Haemost.
2004;
2
1860-1862
2 GPI on the plate is important for the binding of anti-β2 GPI autoantibodies by ELISA.
J Autoimmun.
2002;
18
289-297
2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies.
J Thromb Haemost.
2006;
4
1619-1621
2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and kala-azar.
Clin Exp Rheumatol.
2001;
19
425-430
2 -glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.
Blood.
2003;
102
2717-2723
2 glycoprotein I and prothrombin and risk of thrombosis.
J Thromb Haemost.
2005;
3
1231-1238
2 glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications.
Clin Chem.
2001;
47
1008-1015
2 glycoprotein I cause LA, and their presence correlates strongly with thrombosis.
Blood.
2005;
105
1540-1545
2 glycoprotein I: mutation studies including residues R39 to R43.
Arthritis Rheum.
2007;
56
280-290
sspieran@utmb.edu
